NewEdge Advisors’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $495K | Sell |
5,474
-687
| -11% | -$57.5K | ﹤0.01% | 2155 |
|
|
2026
Q1 | $493K | Sell |
6,161
-20,977
| -77% | -$1.73M | ﹤0.01% | 2003 |
|
|
2025
Q4 | $2.31M | Sell |
27,138
-6
| -0% | -$492 | 0.01% | 999 |
|
|
2025
Q3 | $2.11M | Sell |
27,144
-8,493
| -24% | -$664K | 0.01% | 990 |
|
|
2025
Q2 | $2.79M | Buy |
35,637
+2,665
| +8% | +$199K | 0.01% | 784 |
|
|
2025
Q1 | $2.39M | Sell |
32,972
-71,678
| -68% | -$5.13M | 0.01% | 781 |
|
|
2024
Q4 | $7.75M | Buy |
104,650
+14,683
| +16% | +$1.03M | 0.05% | 376 |
|
|
2024
Q3 | $5.94M | Buy |
89,967
+18,908
| +27% | +$1.37M | 0.04% | 424 |
|
|
2024
Q2 | $6.56M | Buy |
71,059
+17,841
| +34% | +$1.58M | 0.05% | 363 |
|
|
2024
Q1 | $5.09M | Buy |
53,218
+20,818
| +64% | +$1.75M | 0.04% | 387 |
|
|
2023
Q4 | $2.46M | Buy |
32,400
+5,626
| +21% | +$391K | 0.02% | 594 |
|
|
2023
Q3 | $1.85M | Buy |
26,774
+14,487
| +118% | +$1.16M | 0.02% | 622 |
|
|
2023
Q2 | $1.16M | Buy |
12,287
+187
| +2% | +$16.3K | 0.01% | 797 |
|
|
2023
Q1 | $1.02M | Sell |
12,100
-12,618
| -51% | -$992K | 0.01% | 777 |
|
|
2022
Q4 | $489K | Sell |
24,718
-1,826
| -7% | -$141K | 0.01% | 788 |
|
|
2022
Q3 | $2.19M | Buy |
26,544
+2,481
| +10% | +$239K | 0.04% | 405 |
|
|
2022
Q2 | $2.29M | Buy |
24,063
+10,105
| +72% | +$1.05M | 0.04% | 409 |
|
|
2022
Q1 | $1.64M | Sell |
13,958
-2,096
| -13% | -$235K | 0.03% | 478 |
|
|
2021
Q4 | $2.08M | Buy |
16,054
+2,566
| +19% | +$299K | 0.03% | 440 |
|
|
2021
Q3 | $1.53M | Buy |
13,488
+8,485
| +170% | +$969K | 0.04% | 392 |
|
|
2021
Q2 | $518K | Buy |
5,003
+854
| +21% | +$80.5K | 0.01% | 729 |
|
|
2021
Q1 | $347K | Buy |
+4,149
| New | +$351K | 0.01% | 760 |
|
|
2020
Q4 | – | Sell |
-4,156
| Closed | -$332K | – | 1018 |
|
|
2020
Q3 | $332K | Sell |
4,156
-1,173
| -22% | -$91.5K | 0.01% | 690 |
|
|
2020
Q2 | $368K | Sell |
5,329
-8,045
| -60% | -$572K | 0.01% | 623 |
|
|
2020
Q1 | $841K | Sell |
13,374
-9,147
| -41% | -$660K | 0.04% | 346 |
|
|
2019
Q4 | $1.75M | Buy |
22,521
+1,155
| +5% | +$90.2K | 0.07% | 271 |
|
|
2019
Q3 | $1.59M | Buy |
21,366
+11,142
| +109% | +$783K | 0.07% | 260 |
|
|
2019
Q2 | $630K | Buy |
10,224
+2,592
| +34% | +$157K | 0.04% | 353 |
|
|
2019
Q1 | $487K | Buy |
7,632
+873
| +13% | +$49.8K | 0.03% | 408 |
|
|
2018
Q4 | $345 | Buy |
6,759
+1,506
| +29% | +$76.2K | 0.02% | 454 |
|
|
2018
Q3 | $305K | Sell |
5,253
-183
| -3% | -$8.95K | 0.02% | 488 |
|
|
2018
Q2 | $265 | Buy |
5,436
+204
| +4% | +$9.52K | 0.02% | 440 |
|
|
2018
Q1 | $236K | Buy |
+5,232
| New | +$227K | 0.03% | 418 |
|
|
2017
Q3 | – | Sell |
-2,238
| Closed | -$87.7K | – | 593 |
|
|
2017
Q2 | $87.7K | Buy |
+2,238
| New | +$81.7K | 0.02% | 437 |
|
Other funds holding EW
NewEdge Advisors's EW Position: Q2 2026 in Review
NewEdge Advisors reduced its Edwards Lifesciences (EW) stake by 11% in Q2 2026, selling an estimated $57.5K and leaving 5,474 shares worth $495K. The position accounts for ﹤0.01% of the portfolio, ranked #2155.
NewEdge Advisors first reported a position in EW in Q2 2017 and has held it in 34 quarters since. The position peaked at $7.75M in Q4 2024. 1,327 funds tracked by Wall St. Rank hold EW as of Q2 2026.
- NewEdge Advisors held 5,474 shares of Edwards Lifesciences worth $495K as of Q2 2026.
- NewEdge Advisors sold 687 Edwards Lifesciences shares in Q2 2026, an estimated $57.5K.
- Edwards Lifesciences made up ﹤0.01% of NewEdge Advisors's portfolio in Q2 2026, its #2155 holding.
- NewEdge Advisors first reported a position in Edwards Lifesciences in Q2 2017 and has held it in 34 quarters since.
- NewEdge Advisors's Edwards Lifesciences position peaked at $7.75M in Q4 2024.
- 1,327 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.
Based on NewEdge Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.